Spur Therapeutics Completes Enrollment in Phase 1/2 GALILEO-1 Trial of FLT201 in Gaucher Disease and Selects Dose for Planned Phase 3 Trial
July 08, 2024 07:30 ET
|
Spur Therapeutics
Single infusion of FLT201 at low dose of 4.5e11 vg/kg demonstrates compelling safety and benefit Expect to initiate Phase 3 registrational trial in 2025 LONDON, July 08, 2024 (GLOBE NEWSWIRE) --...
Spur Therapeutics Presents Promising New Data from its GBA1 Parkinson’s Disease Research Program
July 01, 2024 07:00 ET
|
Spur Therapeutics
Rationally engineered GCase85 enzyme reduces α-Synuclein accumulation, which plays a key role in the development and progression of Parkinson’s, in neuronal cells more effectively than wildtype GCase ...
Spur Therapeutics to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 20, 2024 07:00 ET
|
Spur Therapeutics
Spur Therapeutics to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Spur Therapeutics (Formerly Freeline) Announces New Name and Brand
June 17, 2024 07:00 ET
|
Spur Therapeutics
With a mission to redefine what gene therapy can do, Spur is optimizing every component of its product candidates to develop a new generation of gene therapies Spur is advancing two potentially...
Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting
May 09, 2024 06:00 ET
|
FREELINE THERAPEUTICS LIMITED
Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentatio
Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
April 24, 2024 16:00 ET
|
FREELINE THERAPEUTICS LIMITED
Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Acquisition of Freeline by Syncona Becomes Effective
February 20, 2024 07:00 ET
|
FREELINE THERAPEUTICS LIMITED
Acquisition of Freeline by Syncona Becomes Effective
Freeline Shareholders Approve Acquisition by Syncona
February 12, 2024 12:00 ET
|
FREELINE THERAPEUTICS LIMITED
Freeline Shareholders Approve Acquisition by Syncona
Syncona to Acquire Freeline Therapeutics
November 22, 2023 07:30 ET
|
FREELINE THERAPEUTICS LIMITED
Syncona to Acquire Freeline Therapeutics
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress
October 25, 2023 02:01 ET
|
FREELINE THERAPEUTICS LIMITED
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Con